Kohei Shitara, MD, National Cancer Center Hospital East, Chiba, Japan, discusses 3-year follow-up data from the Phase III CheckMate 649 trial (NCT02872116) of first-line nivolumab and chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC). Previous follow-ups have demonstrated the superiority of chemoimmunotherapy over chemotherapy alone, and a durable progression-free survival was observed in the 3-year follow-up with no additional toxicities reported. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.